AbbVie
AbbVie's Telisotuzumab Vedotin Effective in NSCLC Patients With High, Intermediate c-MET Expression
Premium
The Phase II results bolster the firm's confidence in the c-MET expression cutoff it has established in an ongoing Phase III trial of the drug.
The firms expect to seek regulatory approval for a subretinal version of the therapy in 2026 though they are also developing a suprachoroidal formulation.
ImmunoGen Achieves Full FDA Approval for Elahere in Folate Receptor Alpha-Positive Ovarian Cancer
The agency made the decision after reviewing results from the confirmatory Phase III MIRASOL clinical trial.
Kura Oncology Begins Testing Menin Inhibitor With Standard Therapies in Phase I AML Trial
The KOMET-008 trial of ziftomenib combinations will involve AML patients harboring either NPM1 mutations or KMT2A rearrangements.
AbbVie Extends License Deal With Scripps Research's Calibr-Skaggs for Switchable CAR-T Platform
AbbVie will develop cell therapies for solid tumors and autoimmune diseases, as it maintains exclusive access to the platform for five years.